dagl

DAGLβ-IN-1，一种针对二酰基甘油脂肪酶 β (DAGLβ) 的抑制剂，可用作DAGL特异性活性探针的通用中间体。

DO34 analog 是二酰基甘油脂肪酶 α (DAGLα) 的抑制剂，DO34 analog 也是 DO34 的一个类似物。

DO34 是一个具有选择性和高效性的二酰基甘油脂肪酶 ( DAGL-α/β) 抑制剂，可损害小鼠的恐惧消退，可用于研究脂多糖炎症性疼痛。

RHC 80267 (U-57908) 是一种选择性二酰基甘油脂酶(DAGL)抑制剂，对犬血小板的IC50为 4 μM。它抑制COX 活性和磷脂酰胆碱的水解，还抑制胆碱酯酶活性，IC50为 4 μM，增强乙酰胆碱引起的松弛。

Midaglizole hydrochloride ((±)-DG5128) (DG5128) 是有效的 α2-肾上腺素受体拮抗剂。Midaglizole hydrochloride (DG5128) 对 α2-肾上腺素能受体的亲和力 (pKi= 6.28) 比 α1-肾上腺素能受体高 7.4 倍。

(Rac)-Daglutril (SLV 306 acetic acid) 是 Daglutril 的消旋体。Daglutril 是一种口服活性的混合中性内肽酶/内皮素转化酶抑制剂，正在开发用于治疗原发性高血压和充血性心力衰竭。

Midaglizole ((±)-DG5128 free base, DG5128 free base) 是一种有效的α2-adrenoceptor 拮抗剂。Midaglizole 是一种降血糖药。Midaglizole 在具有升高血压并降低血糖水平的作用。

Vildagliptin (LAF237) 是一种选择性二肽基肽酶IV (DPP-IV) 抑制剂，在人 Caco-2 细胞中抑制 DPP-IV 的IC50为 3.5 nM。它具有出色的口服生物利用度和降血糖活性。

Daglutril, a NEP/ECE inhibitor, is potentially used for the treatment of hypertension, heart failure andpulmonary. Daglutril inhibits systemic conversion of big endothelin-1 in humans.

Edaglitazone (R-483) 是一种具有口服活性、选择性和高效性的 PPARγ 激动剂，对 PPARα 和 PPARγ均显示出亲和力。Edaglitazone 显示出抗血小板活性，可用于研究糖尿病和肥胖症。

Vildagliptin carboxylic acid metabolite is the major metabolite of the dipeptidyl peptidase 4 (DPP-4) inhibitor vildagliptin in humans. Vildagliptin carboxylic acid metabolite has an IC50 value of 477 μM for DPP-4 in human Caco-2 cells. It is formed from hydrolysis of the cyano group on vildagliptin.

Vildagliptin dihydrate (LAF237 dihydrate) is a powerful and stable dipeptidyl peptidase IV (DPP-IV) inhibitor, demonstrating selectivity with an IC50 of 3.5 nM in human Caco-2 cells. This compound exhibits exceptional oral bioavailability and significant antihyperglycemic activity [1].

Vildagliptin-d7 是 Vildagliptin 的氘代化合物。Vildagliptin 的 CAS 号为 274901-16-5。Vildagliptin 是一种选择性二肽基肽酶IV (DPP-IV) 抑制剂，在人 Caco-2 细胞中抑制 DPP-IV 的IC50为 3.5 nM。它具有出色的口服生物利用度和降血糖活性。

Vildagliptin (Standard) 是 Vildagliptin 的标准品，适用于定量分析、质量控制及生化实验等相关研究。Vildagliptin (LAF237) 是一种选择性二肽基肽酶IV (DPP-IV) 抑制剂，在人 Caco-2 细胞中抑制 DPP-IV 的IC50为 3.5 nM。它具有出色的口服生物利用度和降血糖活性。

LEI-106是一种有效的DAGL-α(sn-1-Diacylglycerol lipase α)/ABHD6（α/β-hydrolase domain 6）双重抑制剂，Ki值分别为 0.7和0.8 μM，可用于研究肥胖和代谢综合征。

Spinosyn Daglycone (A-83543D aglycone) 是杀虫剂 Spinosyn D 的苷元形式。不同于 Spinosyn D，Spinosyn D 苷元对 H. virescens（烟芽虫）新生幼虫无毒（LC50=>64 ppm）。

In humans, two forms of diacylglycerol lipase, DAGLα and DAGLβ, generate the endocannabinoid 2-arachidonoyl glycerol by attacking DAG at the sn-1 position. O-7460 is a selective inhibitor of 2-AG biosynthesis via DAGLα (IC50 = 690 nM). It demonstrates much weaker inhibition towards human monoacylglycerol lipase and rat brain fatty acid amide hydrolase (IC50s > 10 μM) and does not bind to CB1 or CB2 cannabinoid receptors (Kis > 10 μM). At 0-12 mg/kg, i.p. in mice, O-7460 was reported to dose-dependently inhibit high-fat diet intake and reduce body weight.

PNU-EDA-Gly5 is a DNA topoisomerase I inhibitor-based oligo-glycine linker-payload used for the synthesis of antibody-drug conjugates (ADCs). It consists of the DNA topoisomerase I inhibitor PNU-159682 and the linker EDA-Gly5.

3',4',7-Trihydroxyflavone 是分离自蚕豆荚的黄酮苷元化合物。

Taikuguasin D aglycon 是一种天然产物，可用于生命科学领域的相关研究。其产品编号为 TN6311，CAS号为 2185847-09-8。

Body Protection Compound 157 (BPC 157) is a pentadecapeptide derived from BPC, identified in gastric juice, exhibiting diverse biological activities. At 2 µg/ml, BPC 157 enhances primary rat tendon fibroblast cell migration and F-actin formation. Furthermore, doses of 0.01 and 10 µg/kg, intraperitoneally (i.p.), mitigate paw swelling, bone erosion, and mononuclear cell infiltration in the joints of rats with rheumatoid arthritis induced by complete Freund's adjuvant (CFA). It also diminishes gastric ulcer size in rats caused by indomethacin, aspirin, or diclofenac at these doses. Additionally, BPC 157 reduces catalepsy duration and tremor severity in a mouse model of Parkinson's disease triggered by MPTP.

KT109 is a selective inhibitor of DAGLβ (IC50 = 42 nM). KT109-treated wild-type mice displayed reductions in LPS-induced allodyni as well as in DAGL-β (-/-) micea. Repeated KT109 administration prevented the expression of LPS-induced allodynia, without ev

LEI105 is a potent, highly selective, and reversible inhibitor of DAGL-α and DAGL-β.

DO53 is a negative control for DO34, not inhibiting DAGL.